Optimal Timing of Thrombolytic Therapy in Acute Ischaemic Stroke
作者:
Ken Madden,
期刊:
CNS Drugs
(ADIS Available online 2002)
卷期:
Volume 16,
issue 4
页码: 213-218
ISSN:1172-7047
年代: 2002
出版商: ADIS
关键词: Stroke, treatment;Thrombolytics, therapeutic use
数据来源: ADIS
摘要:
The clinical benefit of thrombolytic therapy for patients experiencing acute cerebral ischaemia has been demonstrated by both clinical trials and phase IV studies. However, such treatments must be initiated in a rapid manner, with treating physicians adhering to strict protocols designed to minimise delays and maximise safety. The efficacy of intravenous drug administration has been established with alteplase (recombinant tissue plasminogen activator; tPA) and ancrod, but only if these drugs can be administered within 3 hours of symptom onset. The use of alteplase beyond this timeframe, or outside of established protocols, may be hazardous. The use of alternative intravenous thrombolytic agents, such as streptokinase, also appears hazardous. Intra-arterial delivery of thrombolytic drugs such as pro-urokinase may extend clinical benefit to the 6-hour time frame.
点击下载:
PDF
(202KB)
返 回